Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows
We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...
Regeneron (NASDAQ:REGN) and Sanofi Get Japan Green Light for Smokers’ Lung Disease Treatment
Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...
Fierce Biotech12d
Sanofi pays $600M upfront for Dren Bio's bispecific in latest immunology play
In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...
Regeneron, Sanofi announce Dupixent authorization in Japan
Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...
BioSpace11d
Sanofi Commits up to $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...
Zacks.com on MSN11d
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...
Yahoo Finance26d
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
We note that Sanofi records global net product sales of Dupixent and Kevzara, while Regeneron records its share of profits/losses in connection with the global sales of both drugs. Dupixent’s ...
Pharmabiz3d
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...